By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences said today that a Nasdaq panel has agreed to allow it to remain listed on the exchange while it tries to regain compliance with two listing requirements.

Pressure Bio said that the Nasdaq Listing Qualifications Panel notified the firm on March 7 that it is extending the deadline to regain compliance with a listing requirement calling for at least $2.5 million in stockholder equity. Pressure Bio will now have until March 23 to regain compliance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.